Click above for a quick overview
The financial landscape for physician practices in 2026 is defined by a sharp contradiction: clinical demand is growing, but the margins that sustain independent and mid-size practices continue to narrow. Rising operating costs, ongoing staffing challenges, payer complexity, and a bifurcated 2026 Medicare conversion factor — offering 3.77% increases for advanced alternative payment model (APM) participants and 3.26% for non-participants, alongside a new -2.5% efficiency adjustment on non-time-based services — are pressuring practice economics from every direction. At the same time, the pace of technology adoption in healthcare has accelerated in ways that would have been difficult to predict even three years ago.
Practices that embrace the right mix of technology, operational strategy, and revenue diversification are finding ways not just to survive, but to grow. Those that wait risk falling behind — not only financially but in their ability to attract and retain patients and staff.
This article explores 18 technologies and service strategies that medical practices should evaluate in 2026. Each one is grounded in practical implementation considerations: reimbursement realities, workflow impact, compliance, and the staffing and infrastructure needed to make them work. Whether your practice is already using several of these or just beginning to explore new revenue opportunities, the goal is to help you make smarter, more strategic decisions about where to invest your time and resources.
In This Article
When we first published a version of this article in 2023, many of the technologies discussed were still emerging or in early adoption. The past three years have brought meaningful shifts in regulation, reimbursement, and technology maturity that change the calculus for medical practices.
The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) is now in effect. Released in January 2024, this rule requires impacted payers — including Medicare Advantage organizations, Medicaid managed care plans, CHIP, and qualified health plans on the federal exchange — to begin meeting new prior authorization process requirements and public reporting obligations as of January 1, 2026. The more complex FHIR-based API requirements carry a compliance deadline of January 1, 2027. Practices that invest in EHR interoperability now will be positioned to benefit as payer systems come online.
Remote patient monitoring billing has become significantly more flexible. The CY 2026 Medicare Physician Fee Schedule introduced two new RPM CPT codes — 99445 for device supply covering 2–15 days of data transmission (rather than the previous 16-day minimum), and 99470 for 10 minutes of treatment management services (down from the previous 20-minute threshold). Parallel changes were made for Remote Therapeutic Monitoring with new codes 98985 and 98979.
AI in healthcare operations has moved from pilot projects to production. Ambient AI scribes are now deployed at enterprise scale across major health systems. On the revenue cycle side, AI-powered tools for eligibility verification, prior authorization, denial prevention, and claims optimization are moving from experimental to operational. CMS itself launched the WISeR (Wasteful and Inappropriate Service Reduction) model in January 2026, piloting AI-supported prior authorization for traditional Medicare in six states.
Digital health and connected care have become standard, not supplemental. Telemedicine, remote monitoring, digital therapeutics, and wearable-integrated care pathways are no longer pandemic-era workarounds — they are increasingly woven into the way practices deliver care, engage patients, and generate revenue.
Artificial intelligence is reshaping every phase of the revenue cycle, from patient scheduling and eligibility verification through claims submission, denial management, and collections. Unlike the broad AI promises of a few years ago, today's tools are purpose-built for specific RCM workflows and increasingly demonstrate measurable returns.
Why it matters now: Prior authorization alone costs the U.S. healthcare system tens of billions of dollars annually in administrative overhead. According to the American Medical Association, physicians complete an average of nearly 39 prior authorizations per week, with staff spending roughly 12–13 hours weekly managing these requests. AI-driven automation can flag claims at high risk of denial before submission, auto-populate prior authorization documentation based on clinical data, verify eligibility in real time, and prioritize follow-up on aged accounts receivable.
Revenue and operational impact: Practices that adopt AI-driven denial prevention can shift from reactive appeals workflows to proactive error correction, reducing first-pass denial rates and shortening days in A/R. While AI-assisted coding tools can improve documentation specificity, they introduce significant compliance risks. The HHS-OIG and DOJ are actively monitoring AI-driven "upcoding" as a primary fraud vector, and providers must maintain strict human-in-the-loop review protocols to mitigate False Claims Act liabilities.
🔧 2026 Implementation Note: As payers begin complying with CMS-0057-F requirements for electronic prior authorization and FHIR-based APIs, practices with EHR systems and RCM platforms that support these standards will benefit first. Evaluate your current technology stack's readiness for electronic prior auth workflows, and work with your RCM partner to understand what AI-powered capabilities are available or on the roadmap.
Ambient AI scribes — tools that use large language models to listen to patient-clinician conversations and generate structured clinical notes — have moved from niche pilots to widespread deployment in 2026. The VA has rolled the technology out nationwide, and at least one major EHR vendor now includes ambient AI documentation at no additional cost to subscribers.
Why it matters now: Clinical documentation burden remains one of the leading drivers of physician burnout. Time-motion studies consistently show that for every hour of direct patient care, physicians spend approximately two hours on EHR tasks and administrative work. Ambient AI scribes can reduce documentation time, improve the quality and completeness of clinical notes, and allow physicians to be more present during patient encounters.
Revenue and operational impact: Beyond the quality-of-life benefits, more complete and accurate documentation can improve coding accuracy and capture. Some early-adopter health systems have reported increases in work relative value units (wRVUs) and more comprehensive diagnosis documentation per encounter — not through upcoding, but by reducing under-documentation that occurs when busy clinicians omit clinically relevant details. Practices also see potential to increase patient throughput when physicians spend less time on after-hours notes.
🔧 2026 Implementation Note: The ambient AI scribe market now includes more than 50 vendors. Evaluate options based on EHR integration depth, specialty-specific performance, data privacy policies, and automated coding suggestion capabilities. Physicians must rigorously review AI-generated notes before signing — "automation bias" poses severe malpractice and False Claims Act risks if unperformed exams are documented. Practices must also implement documented patient consent protocols for audio recording to comply with state wiretapping laws.
RPM uses connected devices to collect and transmit patient health data — blood pressure, weight, pulse oximetry, glucose levels, and more — to clinical teams for review and intervention. It has been a growing revenue opportunity for practices since CMS established dedicated billing codes, and the 2026 updates make it substantially more accessible.
Why it matters now: The new short-duration RPM codes (CPT 99445 and 99470) eliminate the longstanding requirement that practices collect at least 16 days of physiologic data before billing. Practices can now bill for as few as 2–15 days of data transmission and for as little as 10 minutes of treatment management time. This opens RPM to acute and episodic use cases — post-surgical recovery, medication adjustments, care transitions — that were previously unbillable.
Revenue and operational impact: RPM generates recurring monthly revenue per enrolled patient through device supply and treatment management codes. With the new shorter-duration options, practices can enroll patients who would not have met the previous 16-day threshold, expanding the eligible population. RPM also supports better clinical outcomes through early intervention, which can reduce costly emergency visits and hospitalizations — a valuable differentiator in value-based contracts.
| Category | Short-Duration (New) | Standard Duration | Note |
|---|---|---|---|
| Device Supply | CPT 99445 (~$47) — 2–15 days | CPT 99454 (~$47) — 16+ days | Mutually exclusive per calendar month |
| Treatment Mgmt | CPT 99470 (~$26) — 10 min | CPT 99457 (~$52) — 20 min | Mutually exclusive per calendar month |
🔧 2026 Implementation Note: Ensure your RPM technology vendor supports the new 2–15 day billing window. Many legacy platforms were built around the 16-day model and may need updates. Document the clinical rationale for short-duration monitoring, including start and end dates and the type of data collected. Train clinical and billing staff on the distinction between short-duration and standard-duration codes — they cannot be billed together in the same calendar month.
The shift toward electronic prior authorization, driven by CMS-0057-F, represents one of the most significant administrative changes in recent years. While the full API requirements do not take effect until January 2027, the operational and reporting requirements that began on January 1, 2026, are already changing payer behavior.
Why it matters now: Prior authorization has long been one of the most time-consuming and frustrating administrative processes for medical practices. The move toward FHIR-based electronic workflows promises to reduce turnaround times, eliminate fax-and-phone cycles, and provide real-time visibility into authorization status and requirements. Beginning March 31, 2026, CMS requires impacted payers to publicly report prior authorization metrics, including approval rates, denial rates, and average turnaround times. Practices should also monitor the CMS WISeR model, which launched in January 2026 to test AI-driven prior authorization for select procedures in Original Medicare.
Revenue and operational impact: Faster prior authorization decisions reduce care delays, improve patient satisfaction, and allow practices to schedule procedures with greater confidence. Reduced administrative time on prior auth frees staff to focus on higher-value work. Over time, practices that have integrated their EHR workflows with payer APIs will experience significantly less friction than those still relying on manual processes.
🔧 2026 Implementation Note: Work with your EHR vendor to understand their roadmap for FHIR-based prior authorization support, including Coverage Requirements Discovery (CRD), Documentation Templates and Rules (DTR), and Prior Authorization Support (PAS) implementation guides. These are not yet mandated by CMS, but they represent the industry direction and will increasingly be expected by payers.
Telemedicine has matured well beyond its pandemic-era surge. In 2026, it functions as a standard care delivery modality for many specialties, supported by established billing codes, expanded payer acceptance, and patient demand for convenience.
Why it matters now: Telemedicine enables practices to extend their reach, reduce no-show rates, and improve access for patients who face transportation, mobility, or scheduling barriers. For practices in competitive markets, offering virtual visit options is increasingly a baseline patient expectation rather than a differentiator.
Revenue and operational impact: Virtual visits can improve provider utilization by filling schedule gaps, reducing in-person visit overhead, and enabling practices to serve patients across a broader geographic area where state licensing permits. Telemedicine also complements RPM and chronic care management programs, creating a connected care model that generates multiple reimbursable touchpoints per patient.
🔧 2026 Implementation Note: Telehealth flexibilities enacted during the pandemic have been extended through congressional continuing resolutions, but the permanence of some provisions remains subject to legislative action. Stay current on federal and state telehealth policy developments, including audio-only visit rules, originating site requirements, and cross-state licensing. Invest in a telehealth platform that integrates with your EHR and scheduling workflows rather than operating as a standalone system.
Digital therapeutics (DTx) are evidence-based software programs designed to prevent, manage, or treat medical conditions. Unlike general wellness apps, DTx products are typically validated through clinical trials and, in some cases, require FDA authorization. They are used for conditions including substance use disorders, insomnia, chronic pain, diabetes management, and mental health conditions.
Why it matters now: As the evidence base for digital therapeutics grows and payer coverage expands, practices have an opportunity to offer these tools as adjunctive or standalone treatments. For practices focused on chronic disease management, behavioral health, or pain management, DTx can extend the care team's reach between visits and improve treatment adherence.
Revenue and operational impact: Medicare has established specific reimbursement pathways for FDA-cleared Digital Mental Health Treatment (DMHT) devices via HCPCS codes: G0552 for supply and onboarding, G0553 (~$20.06) for the first 20 minutes of monthly management, and G0554 (~$19.73) for additional increments. For practices in value-based care arrangements, DTx can help improve quality metrics and reduce the total cost of care.
🔧 2026 Implementation Note: Look for digital therapeutics that integrate with your EHR and patient engagement platforms. The most practical implementations are those where prescribing, monitoring, and outcomes tracking happen within existing clinical workflows rather than requiring separate portals or manual data entry.
Consumer and medical-grade wearable devices — smartwatches, continuous glucose monitors, connected blood pressure cuffs, pulse oximeters, and activity trackers — are generating an unprecedented volume of patient health data. The question for practices is how to translate that data into clinical value and revenue.
Why it matters now: Wearable devices are increasingly capable of detecting clinically meaningful signals: atrial fibrillation, sleep apnea indicators, blood oxygen trends, and activity patterns. When integrated into RPM or chronic care management programs, wearable data can support earlier interventions and better-informed clinical decisions. Patient willingness to use these devices is high, driven by the mainstream adoption of consumer health technology.
Revenue and operational impact: Wearable device data can support RPM billing when the devices meet CMS requirements for physiologic monitoring. Beyond direct reimbursement, wearable-integrated care programs can improve patient engagement and retention, enhance chronic disease management outcomes, and strengthen a practice's position in value-based contracts.
🔧 2026 Implementation Note: Not all consumer wearables qualify for RPM billing — the devices must meet specific criteria for data transmission and clinical-grade monitoring. Work with your RPM platform vendor to identify which devices are supported and ensure data flows into your clinical workflow in a format that supports documentation and billing requirements.
Genetic and genomic testing continues to expand in clinical utility and accessibility. Pharmacogenomic testing to guide medication selection, hereditary cancer risk panels, carrier screening, and whole-exome sequencing for rare disease diagnosis are all becoming more routine in appropriate clinical settings.
Why it matters now: As the cost of genetic testing has continued to decline and the clinical evidence base has expanded, more payers are covering these tests for indicated populations. Pharmacogenomics, in particular, offers practices the opportunity to improve prescribing accuracy, reduce adverse drug events, and demonstrate value in patient outcomes — all while generating billable services.
Revenue and operational impact: Genetic testing can be billed as a laboratory service, and the interpretation and counseling associated with results can generate evaluation and management charges. While clinically valuable, genetic testing is heavily scrutinized for federal healthcare fraud. Financial relationships with reference labs must strictly comply with the Stark Law, the Anti-Kickback Statute, and EKRA, and testing must be driven strictly by documented medical necessity.
🔧 2026 Implementation Note: Genetic testing is subject to complex billing and coverage rules that vary by payer. Work with your billing team to understand the specific CPT codes, diagnosis requirements, and prior authorization policies. Consider whether your practice has the clinical expertise to interpret results in-house or whether partnering with a genetic counseling service is more appropriate.
Medicare's Chronic Care Management and Principal Care Management programs allow practices to bill for non-face-to-face care coordination services provided to patients with multiple chronic conditions or a single high-complexity condition. These programs have been available for several years but remain underutilized by many practices.
Why it matters now: CCM and PCM generate recurring monthly revenue for care coordination activities that many practices are already performing but not billing for — medication reconciliation, care plan updates, coordination with specialists, patient check-ins, and caregiver communication.
| Code | Reimbursement | Patient Criteria |
|---|---|---|
| G0556 | ~$16/month | Patients with one or fewer chronic conditions |
| G0557 | ~$54/month | Patients with two or more chronic conditions |
| G0558 | ~$117/month | Qualified Medicare Beneficiaries with two or more chronic conditions |
Revenue and operational impact: A well-structured CCM program can generate meaningful monthly revenue per enrolled patient, with the potential to scale across a practice's eligible patient panel. Beyond direct reimbursement, CCM programs improve care continuity, reduce hospitalizations and emergency visits, and enhance patient loyalty and satisfaction.
🔧 2026 Implementation Note: Successful CCM programs require dedicated staff or technology support for enrollment, consent management, time tracking, and documentation. Evaluate whether your EHR has built-in CCM workflow tools or whether a third-party platform is needed. Build processes for consistent patient engagement throughout each billing period.
Artificial intelligence is increasingly embedded in diagnostic imaging workflows — radiology, pathology, dermatology, ophthalmology, and cardiology — where machine learning algorithms assist clinicians in detecting abnormalities, triaging studies, and quantifying findings with greater speed and consistency.
Why it matters now: The 2026 CPT code updates include new codes for AI-assisted diagnostic and analytic services, including coronary plaque assessment, perivascular fat analysis, and burn wound imaging. These codes signal that AI-assisted diagnostics are moving from research tools to reimbursable clinical services.
Revenue and operational impact: The new Category I CPT code 75577 reimburses for AI-enabled coronary plaque analysis derived from CCTA, with Medicare establishing payment rates exceeding $950–$1,000 depending on the setting. AI tools can also improve workflow efficiency by prioritizing critical findings and reducing turnaround times. For practices participating in value-based arrangements, improved diagnostic accuracy can contribute to better outcomes and quality scores.
🔧 2026 Implementation Note: AI diagnostic tools must be FDA-cleared for their intended use. Clinicians remain responsible for the final interpretation — AI output should be documented as a component of, not a replacement for, the physician's clinical judgment. Verify that your billing team understands the new AI-specific CPT codes and their documentation requirements.
Biologics remain among the most effective and highest-revenue treatments for chronic conditions including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and certain cancers. The growing availability of biosimilars is creating new options for practices and patients.
Why it matters now: The biosimilar market continues to expand, offering lower-cost alternatives to reference biologics while maintaining clinical efficacy. For practices that administer biologics in office, this creates opportunities to manage drug costs, improve patient access, and maintain strong reimbursement through buy-and-bill arrangements.
Revenue and operational impact: In-office biologic infusions and injections generate significant revenue through drug administration codes and buy-and-bill margins. Biosimilar adoption can reduce drug acquisition costs while maintaining reimbursement rates that are often linked to the reference product. However, payer policies vary widely, and practices must carefully manage inventory, reimbursement expectations, and patient education.
🔧 2026 Implementation Note: Monitor payer formulary changes closely, as some payers are actively steering patients toward preferred biosimilars. Ensure your billing team is current on the specific HCPCS codes and modifiers for biosimilar products. Practices must ensure patient-facing communications regarding biosimilar equivalence adhere strictly to the FDA's December 2025 guidance on promotional communications to avoid misbranding liabilities.
Patient responsibility for healthcare costs continues to grow, driven by high-deductible health plans and rising out-of-pocket maximums. Technology that helps practices estimate, communicate, and collect patient financial obligations is becoming essential for revenue integrity.
Why it matters now: Price transparency regulations, combined with patient expectations for consumer-grade payment experiences, are pushing practices to invest in upfront cost estimation, digital payment options, and automated payment plans. Practices that rely solely on post-visit paper statements are seeing declining collection rates and rising bad debt.
Revenue and operational impact: Real-time eligibility verification, automated cost estimation, point-of-service collection tools, and digital payment platforms can significantly improve patient collections. Reducing the volume of patient statements and collection follow-ups also lowers administrative costs.
🔧 2026 Implementation Note: Evaluate patient payment solutions that integrate with your practice management system and offer features such as payment plan automation, text-to-pay, online portals, and card-on-file capabilities. Ensure compliance with No Surprises Act requirements for good faith estimates. Note that HHS continues to exercise enforcement discretion regarding the mandate to include co-provider and co-facility charges in a convening provider's Good Faith Estimate (GFE) for uninsured or self-pay patients.
Immunotherapy continues to transform cancer treatment, with expanding indications, combination regimens, and new checkpoint inhibitors reaching the market. For oncology practices, staying current with immunotherapy protocols and reimbursement pathways is both a clinical imperative and a financial one.
Why it matters now: The number of FDA-approved immunotherapy indications has grown substantially, and combination approaches involving immunotherapy alongside chemotherapy, radiation, or targeted therapies are becoming standard in many cancer types. For community oncology practices, the ability to offer these treatments locally — rather than referring patients to academic centers — is a key differentiator.
Revenue and operational impact: Immunotherapy drugs carry high acquisition costs but also generate significant reimbursement through drug administration and buy-and-bill models. Practices must carefully manage the financial risk associated with high-cost drug inventory, payer-specific coverage criteria, and the prior authorization requirements that accompany most immunotherapy regimens.
🔧 2026 Implementation Note: Invest in clinical decision support tools that help oncologists navigate the rapidly evolving immunotherapy landscape, including biomarker testing requirements, companion diagnostics, and payer-specific coverage policies. Work closely with your RCM team to ensure prior authorizations are initiated early and that billing accurately reflects the complexity of care delivered.
Regenerative medicine — including platelet-rich plasma (PRP) therapy, stem cell treatments, and other orthobiologic interventions — continues to grow in musculoskeletal, sports medicine, and pain management practices.
Why it matters now: Patient demand for non-surgical, biologic-based treatments for joint pain, tendon injuries, and degenerative conditions remains strong. For practices with the appropriate clinical expertise, regenerative medicine services can attract new patients, differentiate the practice, and generate revenue from services that many patients are willing to pay for out of pocket.
Revenue and operational impact: Practices must be transparent about the evidence base, manage patient expectations carefully, and avoid making unsupported claims about outcomes. The marketing of regenerative medicine, particularly stem cell therapies, carries critical regulatory risk. Recent appellate rulings have affirmed the FDA's authority to regulate clinician-created stem cell therapies, and the FTC continues to prosecute clinics for deceptive marketing resulting in multi-million-dollar penalties.
🔧 2026 Implementation Note: Ensure compliance with FDA guidance on the use of human cells, tissues, and cellular and tissue-based products (HCT/Ps). If offering cash-pay services, implement clear informed consent processes and pricing transparency. Stay current on evolving payer coverage policies, particularly for PRP and other orthobiologic treatments gaining broader acceptance.
While not a revenue-generating technology in the traditional sense, cybersecurity and compliance infrastructure have become non-negotiable investments for medical practices. The financial and operational consequences of a data breach, ransomware attack, or HIPAA violation can be devastating — and the risk is increasing.
Why it matters now: Healthcare remains the most targeted industry for cyberattacks, and small to mid-size practices are increasingly in the crosshairs. Under the anticipated 2026 HIPAA Security Rule updates, practices will face mandatory — rather than addressable — safeguards, including Multi-Factor Authentication (MFA) across all systems accessing ePHI, mandatory encryption, and strict 72-hour disaster recovery capabilities.
Revenue and operational impact: The revenue impact of cybersecurity is primarily defensive — protecting the practice from catastrophic financial losses. A single ransomware event can cost a practice hundreds of thousands of dollars in recovery costs, lost revenue from downtime, and potential legal liability. Compliance with evolving HIPAA requirements is also a prerequisite for participation in many payer contracts and value-based arrangements.
🔧 2026 Implementation Note: Conduct a current HIPAA risk assessment if you have not done so in the past year. Implement multi-factor authentication across all systems that handle protected health information. Ensure your practice has an incident response plan and that staff receive regular cybersecurity awareness training. Evaluate cyber liability insurance coverage against your practice's actual risk profile.
Unlike generative AI, which simply drafts content for a human to review, "agentic AI" acts as an autonomous orchestrator capable of executing multi-step workflows without continuous human input.
Why it matters now: Agentic AI can independently query the EHR for clinical indicators, log into a payer's API portal, submit a prior authorization request, monitor its status, and automatically schedule the patient's procedure upon approval. This end-to-end automation represents a fundamental shift from AI as a tool to AI as a workflow participant.
Revenue and operational impact: Agentic AI enables a "services-as-software" business model, allowing practices to perform complex RCM tasks with software-level margins — fundamentally altering administrative overhead costs.
🔧 2026 Implementation Note: The shift to autonomous AI creates a liability gap. Management staff must review vendor contracts to ensure indemnification clauses specifically address autonomous actions, medical malpractice, and AI "hallucinations" that result in financial loss or patient harm.
A digital twin is a continuously updated virtual replica of a physical entity — ranging from a patient's organ system to a hospital's entire operational workflow.
Why it matters now: Fueled by real-time telemetry from EHRs, wearables, and imaging, digital twins use AI to simulate and predict outcomes before they occur in the real world. The technology is transitioning from research settings into practical operational applications.
Revenue and operational impact: Mid-size practices can utilize digital twins of their clinic workflows to simulate patient flow, predict scheduling bottlenecks, and optimize room utilization to maximize daily throughput.
🔧 2026 Implementation Note: Due to high upfront costs and stringent data privacy regulations, practices should begin by deploying digital twins for administrative and scheduling optimization — which carries a lower regulatory risk profile — before graduating to predictive clinical simulation.
Following the passage of the GENIUS Act in 2025, stablecoins and smart contracts have unlocked the potential for enterprise-grade "programmable payments" in healthcare.
Why it matters now: Traditional healthcare revenue cycles are plagued by multi-day settlement delays and liquidity bottlenecks. Smart contracts introduce "if-then-else" logic that executes financial transfers instantly when specific conditions are met, bypassing traditional clearinghouse friction.
Revenue and operational impact: For medical practices dealing with complex multi-party supply chains, out-of-network cash-pay services, or cross-border medical commerce, stablecoin architecture ensures 24/7/365 settlement without weekend or holiday delays.
🔧 2026 Implementation Note: While consumer adoption for routine copays remains in its infancy, B2B applications are viable today. Practice administrators should consult with banking partners regarding pilot programs for on-chain treasury management and ensure fraud safeguards are in place for unauthorized transactions.
Not every technology on this list is right for every practice. The key is to evaluate each opportunity through the lens of your specific clinical focus, patient population, payer mix, staffing capacity, and strategic goals.
Start with the revenue cycle. Before investing in new clinical services, ensure your existing revenue cycle is operating efficiently. AI-powered RCM tools, electronic prior authorization readiness, and patient financial engagement technology often deliver the fastest and most measurable returns because they improve collection of revenue you are already earning.
Layer in connected care programs. RPM, CCM, and telemedicine create recurring revenue streams that also improve patient outcomes and satisfaction. The 2026 RPM billing changes lower the barrier to entry, making these programs more accessible for practices that have not yet launched them.
Evaluate clinical service expansions carefully. Genetic testing, biologics, immunotherapy, and regenerative medicine can all generate significant revenue — but they also require clinical expertise, staff training, inventory management, and payer navigation. Build the operational foundation before scaling.
Invest in infrastructure. Interoperability, cybersecurity, and compliance are not optional. They are the foundation on which every other technology investment depends.
Navigating the intersection of clinical innovation, revenue optimization, and regulatory compliance is complex — but you don't have to do it alone. Revele's revenue cycle management team works exclusively with medical practices to improve financial performance, streamline operations, and position practices for sustainable growth.
Whether you're evaluating new service lines, working to reduce denials and accelerate collections, or preparing for the interoperability and billing changes taking effect in 2026 and 2027, Revele's Client Performance Managers and RCM specialists bring the expertise and hands-on support to help you move forward with confidence. Revele has recently unlocked its acclaimed RISE Program to all medical practices.